We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $57.68, reflecting a -0.55% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.49%.
The the stock of biopharmaceutical company has fallen by 2.14% in the past month, leading the Medical sector's loss of 4.56% and undershooting the S&P 500's gain of 0.4%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on February 6, 2025. The company is predicted to post an EPS of $1.47, indicating a 13.53% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.59 billion, showing a 0.96% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.93 per share and revenue of $47.56 billion, indicating changes of -87.62% and +5.67%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.27% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #2 (Buy).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 62.08. This expresses a premium compared to the average Forward P/E of 24.81 of its industry.
We can also see that BMY currently has a PEG ratio of 15.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.69 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 61, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $57.68, reflecting a -0.55% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.49%.
The the stock of biopharmaceutical company has fallen by 2.14% in the past month, leading the Medical sector's loss of 4.56% and undershooting the S&P 500's gain of 0.4%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on February 6, 2025. The company is predicted to post an EPS of $1.47, indicating a 13.53% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.59 billion, showing a 0.96% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.93 per share and revenue of $47.56 billion, indicating changes of -87.62% and +5.67%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.27% higher. Bristol Myers Squibb is currently sporting a Zacks Rank of #2 (Buy).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 62.08. This expresses a premium compared to the average Forward P/E of 24.81 of its industry.
We can also see that BMY currently has a PEG ratio of 15.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.69 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 61, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.